- Home
- BIIB vs CPAY Comparison
BIIB vs CPAY Comparison
Compare BIIB & CPAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- CPAY
- Stock Information
- Founded
- BIIB 1978
- CPAY 1986
- Country
- BIIB United States
- CPAY United States
- Employees
- BIIB N/A
- CPAY N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- CPAY EDP Services
- Sector
- BIIB Health Care
- CPAY Technology
- Exchange
- BIIB Nasdaq
- CPAY Nasdaq
- Market Cap
- BIIB 25.1B
- CPAY 24.1B
- IPO Year
- BIIB 1991
- CPAY 2010
- Fundamental
- Price
- BIIB $149.90
- CPAY $345.32
- Analyst Decision
- BIIB Buy
- CPAY Buy
- Analyst Count
- BIIB 26
- CPAY 12
- Target Price
- BIIB $248.00
- CPAY $383.55
- AVG Volume (30 Days)
- BIIB 1.5M
- CPAY 432.0K
- Earning Date
- BIIB 02-11-2025
- CPAY 02-05-2025
- Dividend Yield
- BIIB N/A
- CPAY N/A
- EPS Growth
- BIIB 10.05
- CPAY 9.84
- EPS
- BIIB 11.06
- CPAY 14.01
- Revenue
- BIIB $9,607,500,000.00
- CPAY $3,877,478,000.00
- Revenue This Year
- BIIB N/A
- CPAY $8.44
- Revenue Next Year
- BIIB N/A
- CPAY $11.83
- P/E Ratio
- BIIB $13.55
- CPAY $24.70
- Revenue Growth
- BIIB N/A
- CPAY 4.68
- 52 Week Low
- BIIB $145.07
- CPAY $247.10
- 52 Week High
- BIIB $268.30
- CPAY $385.30
- Technical
- Relative Strength Index (RSI)
- BIIB 35.04
- CPAY 39.57
- Support Level
- BIIB $145.07
- CPAY $334.70
- Resistance Level
- BIIB $149.92
- CPAY $345.93
- Average True Range (ATR)
- BIIB 3.71
- CPAY 7.15
- MACD
- BIIB 0.26
- CPAY -2.64
- Stochastic Oscillator
- BIIB 30.65
- CPAY 29.26
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About CPAY Corpay Inc.
Corpay Inc is a global S&P500 corporate payments company that helps businesses and consumers pay expenses in a simple, controlled manner. Its suite of modern payment solutions helps its customers better manage vehicle-related expenses (such as fueling and parking), travel expenses (e.g. hotel bookings), and payables (e.g. paying vendors). This results in its customers saving time and ultimately spending less.